Capricor Therapeutics
CAPR· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +109.1% in FY2025
Linda Marbán, Ph.D. is the CEO of Capricor Therapeutics and was paid $3.5M in FY2025 (Dec), up 129%.
Pay$100 in the stock at the end of FY21 → $985
Executives3
See all- 1Linda Marbán, Ph.D.Chief Executive OfficerFY2025
- 2Anthony Bergmann, M.B.A.Chief Financial OfficerFY2025
- 3Karen Krasney, J.D.Executive Vice President & General CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCapricor Therapeutics paid its 3 named executives $6.5M in total in FY2025 (Dec). CEO Linda Marbán, Ph.D. was paid $3.5M of that.
| Name | |||
|---|---|---|---|
| Linda Marbán, Ph.D.Chief Executive Officer | |||
| Anthony Bergmann, M.B.A.Chief Financial Officer | |||
| Karen Krasney, J.D.Executive Vice President & General Counsel |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Capricor Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 10, 2026 | FY2025 |
| Annual report | 10-K | Mar 17, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 8, 2025 | FY2024 |
| Annual report | 10-K | Mar 26, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 1, 2024 | FY2023 |
| Annual report | 10-K | Mar 11, 2024 | FY2023 |
